<![CDATA[The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?]]>

Data Readoutpositivebispecific antibodiesPositive

AI Analysis

Summary

The MonumenTAL-6 trial results for bispecific antibodies in multiple myeloma are discussed, with commentary on achieving notably low hazard ratios compared to prior studies in this therapeutic class.

Clinical Trial Data

Outcome Details

MonumenTAL-6 trial results reported with discussion of hazard ratio in bispecific antibody treatment

Importance:5/10

Sentiment:

0.60

multiple myelomabispecific antibodiesMonumenTAL-6clinical trial

Read the original article

Published by Cancer Network on August 6, 2026 7:00 PM

Read Original